AlzeCure Pharma AB

AlzeCure is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions. 💜🧡

[AlzeCure Pharma AB @AlzeCure]

Intervju i Dagens Industri om AlzeCures mångmiljardsaffären med Eli Lilly

Se intervjun här: Alzecure i möjligt miljardavtal med Eli Lilly

AlzeCure Pharma som utvecklar småmolekylära läkemedelskandidater för CNS-sjukdomar med fokus på Alzheimers sjukdom och smärta, har meddeladat att bolaget har ingått ett samarbets- och utlicensieringsavtal med läkemedelsbolaget Eli Lilly and Company (”Lilly”) avseende de globala rättigheterna till Alzheimerprojektet Alzstatin ACD680. AlzeCure kommer att erhålla 10 miljoner USD i upfrontbetalning, utvecklings- och kommersiella milstolpsbetalningar samt royalties i det medelhöga ensiffriga procentintervallet på produktförsäljningen. Det totala avtalsvärdet, exklusive royaltybetalningar, kan överstiga 1 miljard USD.

Till press releasen: AlzeCure Pharma ingår samarbets- och utlicensieringsavtal med Lilly för Alzheimerprojekt – AlzeCure Pharma

#alzecure #Alzstatin #gammasecretasmodulator #alzheimer #dementia #neuroscience #alzheimerfonden #nordnet #avanza #redeye #aktiespararna #swedbank #analysguiden #finwire #placera #abgsundalcollier

[AlzeCure Pharma AB @AlzeCure]

AlzeCure Pharma ingår samarbets- och utlicensieringsavtal med Lilly för Alzheimerprojekt

AlzeCure Pharma AB (publ) (”AlzeCure”) (FN STO: ALZCUR), som utvecklar småmolekylära läkemedelskandidater för CNS-sjukdomar med fokus på Alzheimers sjukdom och smärta, har meddelat att bolaget har ingått ett samarbets- och utlicensieringsavtal med läkemedelsbolaget Eli Lilly and Company (”Lilly”) avseende de globala rättigheterna till Alzheimerprojektet Alzstatin ACD680. AlzeCure kommer att erhålla 10 miljoner USD i upfrontbetalning, utvecklings- och kommersiella milstolpsbetalningar samt royalties i det medelhöga ensiffriga procentintervallet på produktförsäljningen. Det totala avtalsvärdet, exklusive royaltybetalningar, kan överstiga 1 miljard USD.

Alzstatin ACD680 är en gamma-sekretasmodulator som minskar produktionen av det skadliga amyloid-beta-proteinet Aβ42, vilket utgör byggstenen i de amyloida plack som man finner i hjärnan hos patienter med Alzheimers sjukdom. Dessutom ökar ACD680 produktionen av kortare, ofarliga Aβ-proteiner, Aβ37 och Aβ38, vilka kan minska ihopklumpningen av Aβ42 och därmed även reducera uppbyggnaden av skadliga plack i hjärnan.

”Gamma-sekretas modulatorer, som vi har utvecklat inom Alzstatin-plattformen, är småmolekylära läkemedel där verkningsmekanismen har en stark genetisk koppling till sjukdomen”, säger Johan Sandin, Chief Scientific Officer på AlzeCure Pharma.

”Förhoppningen är att Alzstatin-substanserna ska kunna användas för att motverka återuppbyggnaden av skadligt amyloid i hjärnan. På längre sikt kan dessa substanser också fungera som en förebyggande behandling för att förhindra utvecklingen av Alzheimers sjukdom”, säger AlzeCures vd Martin Jönsson.

”Avtalet med Lilly är en viktig milstolpe för AlzeCure och Alzstatin”, fortsätter AlzeCures vd Martin Jönsson

Läs pressreleasen här: AlzeCure Pharma ingår samarbets- och utlicensieringsavtal med Lilly för Alzheimerprojekt – AlzeCure Pharma

#alzecure #Alzstatin #gammasecretasmodulator #alzheimer #dementia #neuroscience #alzheimerfonden #nordnet #avanza #redeye #aktiespararna #swedbank #analysguiden #finwire #placera #abgsundalcollier

[AlzeCure Pharma AB @AlzeCure]

AlzeCure Pharma enters Collaboration & Out-licensing Agreement with Lilly for Alzheimer’s project

AlzeCure Pharma AB (publ) (“AlzeCure”) (FN STO: ALZCUR), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer’s disease and pain, announced today that the company has entered into a collaboration and out-licensing agreement with the pharmaceutical company Eli Lilly and Company (“Lilly”) regarding the global rights to the Alzheimer’s project Alzstatin ACD680.

AlzeCure will receive an upfront payment of $10 million USD, development and commercial milestones, and tiered mid-single digit royalties on sales. The total deal value, excluding royalty payments, may exceed $1 billion USD.

Alzstatin ACD680 is a gamma-secretase modulator that aims to reduce the production of the harmful amyloid-beta protein, Aβ42, which forms the building blocks of the amyloid plaques found in the brains of Alzheimer’s patients. In addition, ACD680 is designed to increase the production of shorter, benign Aβ proteins, Aβ37 and Aβ38, which may reduce the aggregation of Aβ42, thereby also reducing the build-up of harmful plaques in the brain.

“Gamma-secretase modulators, which we have developed within the Alzstatin platform, are small-molecule drugs where the mechanism has a strong genetic link to the disease,” says Johan Sandin, Chief Scientific Officer at AlzeCure Pharma.

“The Alzstatin compounds are hoped to be used to counteract re-accumulation of harmful amyloid in the brain. In the long term, these compounds may also serve as a preventive treatment to prevent the development of Alzheimer’s disease,” says AlzeCure’s CEO Martin Jönsson.

“The agreement with Lilly is an important milestone for AlzeCure and Alzstatin,” continues AlzeCure’s CEO Martin Jönsson.

Read the press release here: AlzeCure Pharma enters into a collaboration and out-licensing agreement with Lilly for Alzheimer’s project – AlzeCure Pharma

#alzecure #Alzstatin #gammasecretasmodulator #alzheimer #dementia #neuroscience #alzheimerfonden #nordnet #avanza #redeye #aktiespararna #swedbank #analysguiden #finwire #placera #abgsundalcollier

[AlzeCure Pharma AB @AlzeCure]

BioStock Panel on the Development in the Alzheimer’s Field
- AlzeCure, Alzinova & BioArctic

I was pleased to be invited to Market Signal, BioStock’s studio program about Nordic life science, to discuss the current development in the Alzheimer's field, together with Alzinova’s CEO Tord Labuda and BioArctic’s CFO, Anders Martin-Löf.

The episode airs on Wednesday morning on BioStock, tune in!

See the panel discussion at BioStock: https/biostock.se

#alzinova #alzecure #bioarctic #biostock #alzheimers #dementia Martin JönssonStiftelsen Flemingsberg Science BioArctic Alzinova AB Tord Labuda
Anders Martin-Löf Cecilia Hallström, PhD Jonas Söderström

[AlzeCure Pharma AB @AlzeCure]

AlzeCure Pain Seminar on TrkA-NAM for Osteoarthritis
- Tuesday May 26, 14:00 CEST

AlzeCure Pharma will host a live online seminar on 26 May from 14:00 to 15:00 CEST focusing on ACD137, the leading drug candidate in the TrkA-NAM pain project.

The company recently published new results* for the TrkA-NAM pain project ACD137, and the purpose of the presentations is to explain the background and opportunities for ACD137. This includes pain indications such as osteoarthritis and chemotherapy-induced neuropathic pain, areas with significant unmet medical needs.
- The presentations will be followed by a Q&A session where participants can submit questions.

The presenters from AlzeCure are Martin Jönsson (CEO), Dr. Märta Segerdahl (Chief Medical Officer), and Dr. Pontus Forsell (Head of Discovery & Research).

Hosted in collaboration with Finwire, the event requires no prior registration and can be followed via:
https://t.co/o5prQ0MbIS
The presentations will be conducted in English and will also be available for later viewing on AlzeCure’s website: https://t.co/WLSBtk8DHn

AGENDA:

14:00 Introduction to AlzeCure Pharma and project status – Martin Jönsson, CEO

14:05 TrkA-NAM in pain – Major unmet medical needs & indication areas – Dr. Märta Segerdahl, CMO

14:20 TrkA-NAM – Next-generation non-opioid analgesics – Dr. Pontus Forsell, Head of Discovery & Research

14:40 Q&A – Martin Westerlund, moderator FinWire

14:55 Concluding Remarks – Martin Jönsson

New publication on TrkA-NAM - Forsell P, et al. Scand J Pain. 2026 Apr 27;26(1). https://t.co/rBiOvjmmQn

#trkanam #ACD123 #alzecure #painmanagement #osteoarthritis #neuropathicpain #chemotherapyinducedneuropathicpain #cna #neuroscience AlzeCure Pharma Pontus Forsell Martin Jönsson Märta Segerdahl Finwire Media

[AlzeCure Pharma AB @AlzeCure]

AlzeCure Presents at ABG Investor Day
- May 21 - Come & Join - Welcome 🫵 🫵

AlzeCure Pharma has been invited to present live at ABG Investor Day May 21, at 13:45 CET.

Our CEO Martin Jönsson will share insights into the company's innovative Alzheimer's and pain pipeline and ongoing development in pain projects and in the Q&A he will be joined by AlzeCure’s Chief Scientific Officer Johan Sandin.

🔗 See us live: https://t.co/PlrcPDfJ7z

You also have the opportunity to apply to participate in person at the event in Stockholm City, at Hotel At Six Brunkebergstorg 6: https://t.co/7amIoMqDdn

Afterwards the presentation will be published at our website under interviews and presentations: https://t.co/WLSBtk8DHn

To the press release: https://t.co/btsGQ7aWMs

#AlzeCure #HealthcareInnovation #Biotech #InvestorRelations Avanza Bank Nordnet Bank AB #alzheimers #alzstatin #neurorestore #CNS #DrugDevelopment AlzeCure Pharma Martin Jönsson ABG Sundal Collier Life Science Cluster Flemingsberg Stiftelsen Flemingsberg Science

[AlzeCure Pharma AB @AlzeCure]

AlzeCure Presents at Redeye Investor Forum
- May 21 - Welcome 🫵 🫵

AlzeCure Pharma has been invited to present live at Redeye Investor Forum event on May 21 at 15:20 CET.

Our CEO Martin Jönsson will share insights into the company's innovative Alzheimer's and pain pipeline and ongoing development in pain projects and in the Q&A he will be joined by AlzeCure’s Chief Scientific Officer Johan Sandin.

🔗 See us live: https://t.co/bl66iIXMCa

Afterwards the presentation will be published at our website inter interviews and presentations: https://t.co/WLSBtk8DHn

To the press release: https://t.co/MxKv1PU9ss

#AlzeCure #HealthcareInnovation #Biotech #InvestorRelations
#Redeye #CNS #DrugDevelopment Johan Sandin Martin Jönsson AlzeCure Pharma Redeye Group Life Science Cluster Flemingsberg Stiftelsen Flemingsberg Science

[AlzeCure Pharma AB @AlzeCure]

Intervju med AlzeCures vd Martin Jönsson om bolagets senaste kvartalsrapport, utveckling samt planer.

Intervjun genomfördes av FinWire i samband med att AlzeCure Pharma släppte sin senaste kvartalsrapport den 5 maj 2026.

Se intervjun här: https://t.co/1iMFf9ou5e

Till pressreleasen om kvartalsrapporten: https://t.co/OCJF0Yyi2k

#alzecure #neurorestore #acd856 #alzheimer #dementia #neuroscience #alzheimerfonden #nordnet #avanza #erikpenserbank #redeye #aktiespararna #swedbank #analysguiden#finwire #Alzstatin #gammasecretasmodulator #trkanam #acd440
#LifeScienceClusterFlemingsberg #flemingbergsscience #flemingbergscience #kvartalsrapport #abgsundalcollier

[AlzeCure Pharma AB @AlzeCure]

AlzeCure Pharma published Q1 2026 report.

Continued positive development

“During the first quarter of 2026, our focus was on preparing the Phase II study in Alzheimer’s patients with NeuroRestore ACD856, for which we were awarded a grant of EUR 2.5 million from the European Innovation Council (EIC). In addition, we successfully advanced the Phase Ib clinical trial with ACD856, further expanding the therapeutic dose window to increase our opportunities to address multiple indications. During the quarter, we also continued preparing for a potential registrational study for the pain project Painless ACD440. In February, ACD440 was granted orphan drug designation by the European Medicines Agency. We also remained active in business development at international conferences and published new data from our NeuroRestore project at the world-leading Alzheimer’s conference AD/PD 2026, which was held in Copenhagen in March.” – Martin Jönsson, CEO

Significant events during the period January – March 2026

In February 2026, the pain project ACD440 was granted orphan drug designation in Europe by the EMA.

AlzeCure presented new preclinical data concerning NeuroRestore ACD856 at the AD/PD Alzheimer’s conference in mid-March.

Significant events after the end of the period

In April, the company announces that the last participant has completed treatment in AlzeCure's clinical phase Ib study with NeuroRestore ACD856.
In April, the board of directors, supported by the authorization granted by the Annual General Meeting on May 14, 2025, decides to carry out a rights issue of approximately SEK 30.1 million. The issue is, free of charge, 100 percent secured.

Read the full report here: https://t.co/WBgGVfhLuG

#alzecure #interimreport #avanza #nordnet #abgsundalcollier #aktiespararna #redeye #swedbank AlzeCure Pharma Life Science Cluster Flemingsberg

[AlzeCure Pharma AB @AlzeCure]

New AlzeCure publication on our pain project TrkA-NAM targeting osteoarthritis

Our article on the analgesic and knee joint protective effects of TrkA-NAM ACD137 in a model of osteoarthritis is now available online. In moments like this, I miss paper reprints, so I settled for this AI-generated 'happy scientist figure' with a virtual preprint.

TrkA-NAM ACD137 is a highly potent and selective negative allosteric modulator of TrkA for the treatment of pain.

The on-line version can be found using the link below: https://t.co/rBiOvjmmQn

#TrkA #NGF #pain #ScandinavianJournalofpain #osteoarthritis #trkanam #osteoarthritis #painmanagement #neurpathicpain #nociceptivpain #AlzeCure #trkanam #osteoarthritis#painmanagement #neurpathicpain #nociceptivpain Pontus Forsell Märta Segerdahl Johan Sandin Maria Backlund Cristina Parrado Veronica Lidell Gunnar Nordvall AlzeCure Pharma Life Science Cluster Flemingsberg

[AlzeCure Pharma AB @AlzeCure]

Intervju om AlzeCures förestående företrädesemission under maj 2026

Intervju hos Redeye av analytikern Filip Lindkvist med AlzeCures vd Martin Jönsson om den förestående företrädesemissionen som AlzeCure kommer genomföra under maj 2026 vilken redan är säkrad till 100%, utan ersättning till externa parter. Bolaget planerar att ta in drygt 30,1 MSEK

Se intervjun här: https://t.co/y6ZEQajjET

Till pressreleasen om emissionen: https://t.co/LpTdmvVbiZ

#alzecure #emission #abgsundalcollier #redeye #aktiespararna #avanza #nordnet #swedbank

[AlzeCure Pharma AB @AlzeCure]

AlzeCure Pharma carries out a fully secured rights issue of approximately SEK 30.1 million

AlzeCure today announced that the Board of Directors has resolved on a new share issue of approximately SEK 30.1 million, in a coming rights issue, which is secured to 100%, without cost for the Company.

AlzeCure is currently engaged in active and concrete discussions with several external parties regarding potential licensing and collaboration agreements for the Company's drug candidates. The Rights Issue is carried out to strengthen the cash position and provide resources for business development, pending these discussions.

The Rights Issue is fully secured to 100 percent as the Company's two major shareholders, BWG Invest Sàrl and Sjuenda Holding AB, have undertaken, free of charge, to subscribe for all shares not subscribed for by other shareholders or subscription rights holders. Subscription undertakings from the Company's two major shareholders, Board of Directors, management and other larger shareholders amount to approximately SEK 9.3 million, corresponding to approximately 31 percent of the Rights Issue.

"We are very pleased that our major shareholders, as well as all members of the Board of Directors, support our projects by committing to subscribe for their respective pro-rata shares in the Rights Issue. The Company is now at a stage where business development is critical to realizing the value inherent in the project portfolio. The Company is engaged in active discussions with several parties regarding potential licensing and collaboration agreements, and through this share issue the cash position is strengthened to intensify out-licensing efforts and capitalize on the opportunities being discussed. The strong support from existing shareholders means that the transaction is, free of charge, 100% secured, which is very positive," says Martin Jönsson, CEO of AlzeCure Pharma AB.

The subscription price is SEK 1.31 per share.

Read the full press release here: https://t.co/qaLBtkr6fl

#alzecure #nyemission #emission #rightissue #alzheimers AlzeCure Pharma ABG Sundal CollierLife Science Cluster Flemingsberg Stiftelsen Flemingsberg Science Martin JönssonAlzheimerfonden

[AlzeCure Pharma AB @AlzeCure]

AlzeCure Pharma genomför en till 100 procent säkerställd företrädesemission om ca 30,1 MSEK

AlzeCure meddelade idag att styrelsen har beslutat att genomföra en företrädesemission om cirka 30,1 MSEK vilken är till 100% säkerställd till utan kostnad för bolaget, dvs ingen ersättning för att teckna i emissionen kommer att betalas.

AlzeCure för idag aktiva och konkreta samtal med flera externa aktörer kring möjliga licens- och samarbetsaffärer avseende bolagets läkemedelskandidater. Företrädesemissionen genomförs för att stärka kassan och ge resurser till affärsutveckling, i avvaktan på dessa samtal.

Företrädesemissionen är till 100 procent säkerställd genom att Bolagets två huvudägare, BWG Invest Sàrl och Sjuenda Holding AB, vederlagsfritt, förbinder sig att teckna samtliga aktier som inte tecknas av andra aktieägare eller teckningsberättigade.

Teckningsförbindelser från Bolagets två huvudägare, styrelse, ledning och andra större aktieägare uppgår till cirka 9,3 MSEK, motsvarande cirka 31 procent av Företrädesemissionen.

”Det är mycket glädjande att våra större ägare, såväl som samtliga styrelsemedlemmar stödjer våra projekt genom att förbinda sig att teckna sina respektive andelar av Företrädesemissionen. Bolaget befinner sig nu i en fas där affärsutveckling är avgörande för att realisera det värde som finns i projektportföljen. Bolaget för aktiva
diskussioner med flera aktörer om eventuella licens- och samarbetsaffärer och genom denna emission stärks kassan för att kunna intensifiera utlicensieringsarbetet och utnyttja de möjligheter som diskuteras. Det starka stödet av existerande ägare gör att transaktionen, vederlagsfritt, är 100% säkerställd, vilket känns mycket positivt,” säger Martin Jönsson, VD på AlzeCure Pharma AB.

Teckningskursen är satt till 1,31 SEK.

Läs den fullständiga pressreleasen här: https://t.co/LpTdmvVbiZ

#alzecure #nyemission #emission #rightissue #alzheimers AlzeCure Pharma ABG Sundal Collier Life Science Cluster Flemingsberg Stiftelsen Flemingsberg Science Martin Jönsson

[AlzeCure Pharma AB @AlzeCure]

Attending Nordic Health Summit Japan
- April 23-24th 2026

Happy to attend the Nordic Health Summit in Japan, Tokyo to present AlzeCure and our projects in Alzheimer’s and pain for pharmacies companies, investors and other potential partners.

This year the meeting is also having Japan’s Nobel Prize laureate in medicine from 2025, Professor Shimon Sakaguchi, attending the conference and giving a lecture, which is generating additional attention and attendees, and strengthens the ties and relationships between Japan and Sweden.

The meeting is arranged by Business Sweden together with several other Nordic organisations.

More on Professor Shimon Sakaguchi: https://t.co/mugCNXqMjT

#alzecure #businesssweden #flemingsbergsscience #nobelprize #alzheimers Martin Jönsson AlzeCure Pharma Life Science Cluster Flemingsberg Stiftelsen Flemingsberg Science Business Sweden SwedenBIO

[AlzeCure Pharma AB @AlzeCure]

Last patient completed in the additional 1b with NeuroRestore
AlzeCure Pharma announces an important milestone: the last patient has now completed the additional Phase Ib clinical study of ACD856, the lead candidate within the NeuroRestore platform.

The study has progressed according to plan and focuses on evaluating safety, tolerability, and pharmacokinetics at higher repeated doses. ACD856 has previously demonstrated a strong safety profile and the ability to reach the brain and activate pathways linked to cognition and depression.

This progress supports continued development toward Phase II, with potential applications not only in Alzheimer’s disease but also in other areas with significant unmet medical need, such as depression.

ACD856 is a first-in-class candidate with a unique mechanism that may strengthen neuronal communication, improve cognitive function, and offer neuroprotective and anti-inflammatory effects.

Read the full press release here: https://t.co/jnYgCzG9jo

#AlzeCure #Biotech #ClinicalTrials #DrugDevelopment #Neuroscience #Alzheimers #CNS #Pharma #Innovation #Depression #NeuroRestore Johan Sandin Martin Jönsson AlzeCure Pharma

[AlzeCure Pharma AB @AlzeCure]

Continuing Progress in AlzeCure
- AlzeCure Pharma Annual Report 2025.

"With strong progress and many positive events in 2025, our main priority going forward is to prepare for the Phase II clinical trial in Alzheimer’s patients with NeuroRestore ACD856, for which we have received a grant from the EIC. We continue to prepare both our pain project in knee osteoarthritis, TrkA-NAM ACD137, and Alzstatin ACD680 for Phase I clinical trials. We also remain strongly focused on business development with the aim of out-licensing one or more of our projects, including the pain project, ACD440."

Martin Jönsson
CEO of AlzeCure Pharma

Read the full report here: https://t.co/LC4xqraIvp

#AlzeCurePharma #PainResearch #Alzheimers #ClinicalDevelopment#Innovation Martin Jönsson

[AlzeCure Pharma AB @AlzeCure]

Happy Easter 🐣 🐣 🐣
- Have a great one.

#alzecure

[AlzeCure Pharma AB @AlzeCure]

AlzeCure presenterar på Redeye Alzheimer’s Event
- 9 april

AlzeCure kommer att medverka på Redeye Alzheimer’s Theme Event den 9 april där VD Martin Jönsson och CSO Johan Sandin kommer att presentera bolaget och dess projektportfölj inom Alzheimers.

Presentationen följs av en frågestund ledd av Redeyes analytiker Filip Lindkvist.

Deltagandet livesänds och kan följas på:
https://t.co/0YKGioLgGf

AlzeCure kommer presentera kl. 11:15 den 9 april 2026
Plats: Redeye, Mäster Samuelsgatan 42, Stockholm; https://t.co/0YKGioLgGf

#alzecure #redeye #alzheimer Stiftelsen Flemingsberg Science Life Science Cluster Flemingsberg Martin Jönsson Johan Sandin

[AlzeCure Pharma AB @AlzeCure]

Presentation om AlzeCure Pharma hos Aktiespararna av CEO Martin Jönsson

Presentation om AlzeCure Pharma av CEO Martin Jönsson om bolaget och dess projekt inom Alzheimer och smärta, samt om den senaste utvecklingen och bolagets planer.

Presentationen hölls hos Aktiespararna på Stora Aktiedagarna i Stockholm den 11 mars 2026.

Till presentationen: https://t.co/miKY1z4NTE

#aktiespararna #analysguiden #alzecure

[AlzeCure Pharma AB @AlzeCure]

Great Bio Europe in Lisbon
- Now it's over, and time for follow-ups

Very happy with this year’s Bio Europe Spring in Lisbon, meeting pharma companies, partners and investors, presenting and giving an update on AlzeCure’s projects and plans for our projects in Alzheimer’s and pain.

Now it’s time to go home and do all the follow-up based on fruitful meeting.

Happy to have been joined by my friends at Sprint Bioscience, Anne-Marie Wenthzel-Buckhöj and Martin Andersson

Read more on Alzecure and our projects at https://t.co/JorDOcorMT

#newtherapies
#drugdevelopment
#BIOEuropeSpring AlzeCure Pharma Martin Jönsson
#sprintbioscience Anne-Marie Wenthzel-Buckhöj Martin Andersson AlzeCure PharmaLife Science Cluster Flemingsberg SwedenBIO Business Sweden Martin Jönsson